Alternatively, Esfandiari et al. used PVX nanoparticles to transport monoclonal antibodies of herceptin (Trastuzumab), as a targeted therapy in (Her2+) for breast cancer patients [57]. This evidence concerns the gene ERBB2 and breast cancer.